Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO phase 3 trial of patisiran in transthyretin-mediated familial amyloid polyneuropathy
NL-OMON44756Phase 3Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2015
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary transthyretin amyloidosis (hATTR) comparing Patisiran with Placebo (2 arms). Primary endpoint: Change from baseline in modified NIS+7 score. Started Jun 2015; status: active, not recruiting.
02
Drugs
patisiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NL-OMON44756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44756.